Inogen Inc

Inogen operates with a cash-and-equivalents position of $103.7 million, representing 34.7% of total assets, and no long-term debt, resulting in a debt-to-equity ratio of 0.00. The company's liquidity is characterized as low, with a current ratio of 3.12, indicating strong short-term liquidity but no leverage to amplify returns. The price-to-book ratio of 0.91 suggests the market values the company at a discount to its tangible book value, while the price-to-tangible-book ratio of 0.91 aligns with this valuation. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $22.7 million and an operating loss of $30.2 million, translating to a return on equity of -11.83% and a return on assets of -7.62%. These figures indicate a failure to generate returns on invested capital, which is a critical concern in a capital-intensive industry like medical equipment. Inogen's revenue is concentrated in a single business segment focused on portable oxygen concentrators, with no disclosed geographic diversification. The company's 100% revenue concentration in this segment exposes it to demand volatility in the respiratory care market and potential regulatory shifts affecting product approvals. No material geographic diversification is reported, increasing exposure to regional healthcare policy changes. The company's growth trajectory is mixed. While revenue of $348.7 million represents a baseline, the operating cash flow of -$11.2 million and free cash flow of -$12.5 million indicate ongoing cash burn. Analysts project a mean price target of $12.67, implying a 99% upside from the current market price of $6.38, but no specific revenue growth rates are provided in the input data. The absence of capital expenditures in the diluted share count suggests no recent share issuance, but the company's negative net income raises concerns about long-term growth sustainability. Risk factors include liquidity constraints and the absence of long-term debt, which limits financial flexibility. The risk assessment flags no immediate dilution or liquidity pressures, but the company's negative operating cash flow and free cash flow suggest potential future capital needs. No dilution sources are explicitly identified in the input data, but the company's negative net income and cash burn could necessitate future equity raises. Recent events include analyst price targets ranging from $12.00 to $14.00, with a mean recommendation of 2.00 (Buy). No recent filings or transcripts are provided in the input data to assess management commentary or strategic shifts.